#TeamVaccines campaign
The world doesn’t just need COVID-19 vaccines. We need people around the world to feel confident in getting them, when it’s their turn. This campaign is an opportunity for all of us to help spread confidence and trust in the vaccines! Join #TeamVaccines now!
#TeamVaccines
Africa Young Innovators for Health Award
The first edition of the Africa Young Innovators for Health Award aims to promote innovative solutions dedicated to support, equip, protect and train healthcare professionals
Visit the website
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
Call to Action On Routine and Life-Course Immunization in the Context of the COVID-19 Pandemic
Life-course immunization can contribute to healthier, more productive, and longer lives, which enhances the sustainability of healthcare systems
Read More
The African Medicines Agency
AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.
Read More
AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Inventing Medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
The African Medicines Agency
Read More
Health for All in Africa - Our collaborations supporting the SDGs
Read More
Message from Thomas Cueni at AMR Action Fund launch event in Tokyo on 10 July 2020 (Video)
Read More
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
This International Agreement Could Lead To Pandemics Worse Than COVID-19 (Excerpts)
This oped was originally published on International Business Times on 11 April 2021. Imagine if China had refused to share Covid-19's genetic sequences with other countries. Vaccine development would have been delayed indefinitely. Monitoring the virus would have been next to impossible. Thankfully, that didn't happen. Chinese scientists shared the full SARS-CoV-2 sequence on Jan. 10, 2020, thus kickstarting the development of multiple vaccines created...
Read More
Waiving IP rules will not deliver more Covid vaccines
This oped was published on the Financial Times on 25 April 2021 1998, 39 pharmaceutical companies sued Nelson Mandela’s South African government to stop legislation that allowed pharmacists to substitute generic HIV/Aids drugs for brand-name ones. It was one of the dumbest things the industry ever did. What started as a legal battle became a human disaster, and a public relations debacle. Critics accused drug...
Read More
Challenges and solutions to scaling-up COVID-19 vaccine manufacturing capacity
On the first anniversary of the Access to COVID-19 Tools Accelerator (ACT Accelerator), high-level representatives – from pharma and biotech trade associations and vaccine manufacturers from both developed and developing countries – met to discuss the challenges of scaling-up vaccine production and ensuring vaccine equity. Present at the meeting were IFPMA Director General Thomas Cueni, Moderna CEO Stephane Bancel, Roger Connor, President, Vaccines at GSK...
Read MoreLatest Tweets
